Inhaled Bicarbonate Therapy in Cystic Fibrosis
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Inhaled Bicarbonate Therapy in Cystic Fibrosis|
- Study 1A: Determine the acute effects of increasing doses of inhaled bicarbonate on mucociliary clearance.
- Study 1B: Determine the acute effects of inhaled bicarbonate on mucociliary clearance.
- comparison of pre- and post-bicarbonate exhaled breath condensate pH values.
- Safety as determined by pre- and post-clearance assay pulmonary function tests (FEV1)
|Study Start Date:||March 2002|
|Study Completion Date:||December 2006|
|Primary Completion Date:||December 2006 (Final data collection date for primary outcome measure)|
There is evidence that people with CF may have differences in the liquid that lines the surface of their lungs from people without CF. There are two things that are known to be different. One is called bicarbonate secretion, which is the movement of a salt called bicarbonate that is normally present in the blood and lung fluid in all people. The abnormal movement of bicarbonate appears to cause a second abnormality - the liquid in the breathing tubes has more acid than the liquid in patients without CF. These differences may affect the stickiness and thickness of the mucus and limit how well the hairs that line the breathing tubes (cilia) move mucus out of the lungs.
Recent studies in a group of patients with chronic cough looked at the effects of giving an inhaled bicarbonate solution (sodium bicarbonate instead of sodium chloride) on the study subjects' ability to cough up mucus. Compared to the group given inhaled saline, the patients given inhaled bicarbonate were able to cough up approximately three times as much mucus. No clinical studies have looked at whether inhaled bicarbonate improves the ability of the lung in a person with CF to move mucus out of the lung or how this treatment affects lung function in patients with CF.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00177645
|United States, Pennsylvania|
|Children's Hospital of Pittsburgh|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Joseph M Pilewski, MD||University of Pittsburgh|